Extrapolate Robust Translational Insights to Guide Clinical Decisions by Assessing Your Drug’s Mechanism-of-Action, Proving Candidate’s Safety & Accurately Modelling Drug Efficacy
Explore How to Choose Your Predictive PDX, Humanized Mice & In Vitro Models to Assess Biomarkers, TME, Safety & Immune Response for Your CAR, NK & T-Cell Therapies
With commitments to advancing your preclinical and translational oncology research, we were delighted to bring the 9th PREDiCT: Tumor Models Summit to your screens in July.
With the rise of innate killer, allogenic, CAR- and T-cell therapies, the ability to choose best-in-class tumor models is critical for preclinical drug developers, allowing them to effectively model the tumor microenvironment, immune response, further mechanism of action, and biomarker understanding to make an informed clinical decision.
As there is no perfect model and clinical stakes remain high, the 9th PREDiCT: Tumor Models Summit delved into the core challenges of novel cell and combination therapies, and how the progression of next-gen PDX, humanized mice, in vitro and ex vivo model toolbox will improve your translational and clinical confidence to answer critical safety and efficacy questions, predict the toxicity and optimize dosing for patients.
Below are a few highlights from 2021!
- Dedicated streamed content to focus on next-gen tumor models for combination, cellular immune-oncology in drug discovery and development
- Novartis shared how to use a simple xenograft model to effectively assess CAR-T efficacy
- AstraZeneca showed how to guide innovative clinical trials for T-cell based therapies using preclinical data
- Takeda discussed how to leverage single-cell analytics to understand the complexities of the tumor microenvironment
- Harvard Medical School shared how they use multiple tumor models to advance NK cell therapies